Publication
Outcomes in Guillain-Barré Syndrome Following a Second Therapeutic Cycle – A Single-Centre Retrospective Observational Study
| dc.contributor.author | Faustino, P | |
| dc.contributor.author | Coutinho, M | |
| dc.contributor.author | Brum, M | |
| dc.contributor.author | Medeiros, L | |
| dc.contributor.author | Ladeira, F | |
| dc.date.accessioned | 2024-05-03T14:43:07Z | |
| dc.date.available | 2024-05-03T14:43:07Z | |
| dc.date.issued | 2022-10 | |
| dc.description.abstract | Introduction: The treatment of Guillain-Barré Syndrome (GBS) with intravenous immunoglobulin (IVIg) or plasma exchange (PE) reduces time to clinical recovery. Although sometimes used in clinical practice, the benefit of a second treatment cycle is of unproven benefit. Aims: Our aim was to compare GBS prognosis in patients treated with one or two cycles of IVIg or PE. Methods: We selected patients with electrophysiological studies compatible with acute inflammatory demyelinating polyneuropathy or acute motor-sensory axonal neuropathy, from January 2018 to December 2020 in our hospital. Our primary outcome was any improvement in the Guillain-Barré Syndrome Disability Score (GBS-DS) at a mean of twelve weeks. We compared patients treated with one or two treatment cycles with a binary regression. Results: We included twenty-six patients, 65.4% with the classical presentation and 30.8% were treated with two cycles. Patients treated with two cycles presented a higher basal GBS-DS (median 4; IQR 1-5) compared with the group of patients treated with one cycle (median 3; IQR 1-5), p = 0.01. The remaining basal characteristics were similar between groups. The two-cycle treatment regimen did not associate with an improvement in GBS-DS (OR 0.28, 95% CI 0.03-2.35, p = 0.24). Likewise there was no benefit in the need for intensive care unit (OR 2.0, 95% CI 0.37-10.92, p = 0.42) or mechanical invasive ventilation (OR 10.2, 95% CI 0.86-120.96, p = 0.66). Discussion: Our analysis reinforces the recent literature data regarding the absence of benefit of two treatment cycles in patients with GBS. | pt_PT |
| dc.description.version | info:eu-repo/semantics/publishedVersion | pt_PT |
| dc.identifier.citation | J Neurol Sci . 2022 Oct 15:441:120368. | pt_PT |
| dc.identifier.doi | 10.1016/j.jns.2022.120368 | pt_PT |
| dc.identifier.uri | http://hdl.handle.net/10400.17/4889 | |
| dc.language.iso | eng | pt_PT |
| dc.peerreviewed | yes | pt_PT |
| dc.publisher | Elsevier | pt_PT |
| dc.subject | HSJ NEU | pt_PT |
| dc.subject | Guillain-Barre Syndrome* / drug therapy | pt_PT |
| dc.subject | Immunoglobulins, Intravenous* / therapeutic use | pt_PT |
| dc.subject | Plasma Exchange | pt_PT |
| dc.subject | Plasmapheresis | pt_PT |
| dc.subject | Prognosis | pt_PT |
| dc.title | Outcomes in Guillain-Barré Syndrome Following a Second Therapeutic Cycle – A Single-Centre Retrospective Observational Study | pt_PT |
| dc.type | journal article | |
| dspace.entity.type | Publication | |
| oaire.citation.startPage | 120368 | pt_PT |
| oaire.citation.title | Journal of the Neurological Sciences | pt_PT |
| oaire.citation.volume | 441 | pt_PT |
| rcaap.rights | openAccess | pt_PT |
| rcaap.type | article | pt_PT |